Ecnoglutide

Ecnoglutide is a pharmacological agent that is classified as a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist). It is used in the treatment of type 2 diabetes and obesity.

Mechanism of Action

Ecnoglutide works by mimicking the effects of the natural hormone glucagon-like peptide-1 (GLP-1). GLP-1 is released in response to food intake and has several effects that help to control blood glucose levels. It stimulates the release of insulin from the pancreas, inhibits the release of glucagon (a hormone that raises blood glucose levels), and slows gastric emptying. By activating the GLP-1 receptor, ecnoglutide enhances these effects, helping to control blood glucose levels in people with type 2 diabetes.

Clinical Use

Ecnoglutide is used in the treatment of type 2 diabetes. It is typically used in combination with other antidiabetic medications, such as metformin or a sulfonylurea, when these medications alone do not provide adequate control of blood glucose levels. Ecnoglutide may also be used in the treatment of obesity, as it can help to reduce appetite and promote weight loss.

Side Effects

Common side effects of ecnoglutide include nausea, vomiting, diarrhea, and abdominal pain. These side effects are usually mild and tend to decrease over time. More serious side effects can include pancreatitis and allergic reactions.

Pharmacokinetics

Ecnoglutide is administered by subcutaneous injection. It has a long half-life, allowing for once-weekly dosing. Ecnoglutide is primarily excreted in the urine.

See Also

• Glucagon-like peptide-1 receptor agonist
• Type 2 diabetes
• Obesity

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

   This article is a Diabetes-related stub. You can help WikiMD by expanding it!

   This article is a endocrinology stub. You can help WikiMD by expanding it!